Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Xeris Biopharma Holdings Inc shares valued at $9,720 were purchased by Schmid John P. on Mar 14 ’24. At $2.16 per share, Schmid John P. acquired 4,500 shares. The insider’s holdings grew to 11,000 shares worth approximately $21780.0 following the completion of this transaction.
Also, SHERMAN JEFFREY W purchased 5,400 shares, netting a total of over 10,098 in proceeds. Following the buying of shares at $1.87 each, the insider now holds 5,400 shares.
Before that, Pieper Steven had added 28,000 shares to its account. In a trade valued at $54,600, the insider bought Xeris Biopharma Holdings Inc shares for $1.95 each. Upon closing the transaction, the insider’s holdings increased to 28,000 shares, worth approximately $2.33 million.
As published in their initiating research note from Oppenheimer on March 28, 2024, Xeris Biopharma Holdings Inc [XERS] has been an Outperform and the price target has been revised to $5. Analysts at Craig Hallum started covering the stock with ‘”a Buy”‘ outlook in a report released in late August. As of October 21, 2022, Jefferies has initiated its “Buy” rating for XERS. Earlier on April 28, 2022, Craig Hallum initiated its rating. Their recommendation was “a Buy” for XERS stock.
Analyzing XERS Stock Performance
During the last five days, there has been a drop of approximately -4.81%. Over the course of the year, Xeris Biopharma Holdings Inc shares have dropped approximately -15.74%. Shares of the company reached a 52-week high of $3.26 on 02/15/24 and a 52-week low of $1.93 on 04/10/24. A 50-day SMA is recorded $2.53, while a 200-day SMA reached $2.24. Nevertheless, trading volume fell to 1.59 million shares from 0.92 million shares the previous day.
Support And Resistance Levels for Xeris Biopharma Holdings Inc (XERS)
According to the 24-hour chart, there is a support level at 1.94, which, if violated, would cause prices to drop to 1.89. In the upper region, resistance lies at 2.02. The next price resistance is at 2.05. RSI (Relative Strength Index) is 32.82 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.07, which suggests the price will decrease in the coming days. Percent R is at 85.71%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is Xeris Biopharma Holdings Inc subject to short interest?
Stocks of Xeris Biopharma Holdings Inc saw a sharp steep in short interest on Mar 15, 2024 dropping by -0.18 million shares to 9.24 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 9.42 million shares. A decline of -1.95% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.52 of the overall float, the days-to-cover ratio (short ratio) decline to 3.52.
